ACCESS Newswire
23 Jan 2023, 12:35 GMT+10
LONDON, UK / ACCESSWIRE / January 23, 2023 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is pleased to announce the successful completion of its third Process Qualification ('PQ') run of the end-to-end process for the manufacture of HEMO-CAR-T cells. The process was carried out in the Company's current Good Manufacturing Practice ('cGMP') compliant clean rooms. It is being followed by analytical release tests conducted by the Company required to verify the quality of the manufactured HEMO-CAR-T cells. The HEMO-CAR-T cells will also be tested by a third party to ensure they comply with a set of required quality attributes.
This PQ run is the third of minimum three identical manufacturing runs required for the submission of an Investigational New Drug ('IND') application to the US Food and Drug Administration ('FDA'). The IND is needed to obtain authorization from the FDA to commence Phase I clinical trials of HEMO-CAR-T. Following completion of all tests across all PQ runs, data will be compiled for inclusion in the IND submission pack.
Enquiries:
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
Get a daily dose of Cleveland Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Cleveland Star.
More InformationNEW YORK, New York - Global stock indices closed with divergent performances on Tuesday, as investors weighed corporate earnings, central...
TORONTO, Canada: Canadian Prime Minister Mark Carney announced late on June 29 that trade negotiations with the U.S. have recommenced...
Vancouver, Canada: A high-stakes legal showdown is brewing in the world of athleisure. Lululemon, the Canadian brand known for its...
LONDON, U.K.: British oil giant Shell has denied reports that it is in talks to acquire rival oil company BP. The Wall Street Journal...
NEW YORK, New York - U.S. stock markets closed firmly in positive territory to start the week Monday, with the S&P 500 and Dow Jones...
WASHINGTON, D.C.: On Friday, President Donald Trump announced that he was halting trade discussions with Canada due to its decision...
ABU DHABI, 19th June, 2025 (WAM) -- Cleveland Clinic Abu Dhabi has become the first and only research hospital in the UAE to receive...
ABU DHABI, 17th June, 2025 (WAM) -- Cleveland Clinic Abu Dhabi, part of the M42 group, has successfully introduced continuous infusion...
ABU DHABI, 9th June, 2025 (WAM) -- Cleveland Clinic Abu Dhabi has successfully performed the UAE's first robotic cytoreductive surgery...
ABU DHABI,16th May, 2025 (WAM) - Oracle Health, Cleveland Clinic, and G42 today announced a strategic partnership to develop a groundbreaking...
ABU DHABI, 6th May, 2025 (WAM) -- PureHealth and its subsidiary SEHA have partnered with the number one US children's hospital, Cincinnati...
Argentinian composer Lalo Schifrin, the genre-blending film and television composer behind the Mission: Impossible, Bullitt, and Cool...